Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Subjects:

Comparisons between densitometric, biochemical, and hormonal variables and bone remodeling markers of exclusive breastfeeding mothers (EBF) 15 days postpartum and the same EBF moth... by Larissa Brazolotto Ferreira (17671168)

Subjects:

Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Flowchart of the exclusive breastfeeding mothers (EBF) and the exclusive breastfeeding mother-donors (EBF+) who participated in the study. by Larissa Brazolotto Ferreira (17671168)

Subjects:

Timeline of monitoring of exclusive breastfeeding mothers (EBF) and exclusive breastfeeding – donors (EBF+). by Larissa Brazolotto Ferreira (17671168)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

<i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

Subjects:

Data supporting the findings of this study. by Aga E. Gelgie (17661720)

Subjects:

Comparison of densitometric, biochemical, and hormonal variables, and bone turnover markers of EBF + 6 months versus EBF + one year postpartum. by Larissa Brazolotto Ferreira (17671168)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

Subjects:

Open data. by Larissa Brazolotto Ferreira (17671168)

Subjects:

Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

Subjects: